Live Breaking News & Updates on Oramed Pharmaceuticals Company Profile Get Rating

Stay updated with breaking news from Oramed pharmaceuticals company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to "Hold"

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. A number of other research firms have also recently commented on ORMP. Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals in a research report on Friday, February 18th. They set an “overweight” […] ....

Hong Kong , Zurcher Kantonalbank Zurich Cantonalbank , Kevin Rakin , Oramed Pharmaceuticals Inc , Wells Fargo Company , Cantor Fitzgerald , Oramed Pharmaceuticals Company Profile Get Rating , Oramed Pharmaceuticals , Hong Kong Ltd , Royal Bank , Get Rating , Director Kevin Rakin , Kong Ltd , Pharmaceuticals Company Profile , Pharmaceuticals Inc , Nasdaq Ormp , Stocknews Com ,

-$0.19 Earnings Per Share Expected for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) This Quarter

Brokerages predict that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will report earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.23). Oramed Pharmaceuticals reported earnings of ($0.17) per share during […] ....

Oramed Pharmaceuticals Inc , Zacks Investment Research , Oramed Pharmaceuticals , Invesco Ltd , Cantor Fitzgerald , Moors Cabot Inc , Oramed Pharmaceuticals Company Profile Get Rating , Millennium Management , Get Rating , Zacks Investment , Oramed Pharmaceutical , Capital Management , State Street Corp , Pharmaceuticals Company Profile , Nasdaq Ormp ,

$700,000.00 in Sales Expected for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) This Quarter

Wall Street analysts forecast that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will announce $700,000.00 in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $670,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 4.5%. […] ....

Thomson Reuter , Oramed Pharmaceuticals Inc , Zacks Investment Research , Blackrock Inc , Oramed Pharmaceuticals , Invesco Ltd , Greylin Investment Mangement Inc , Cantor Fitzgerald , Oramed Pharmaceuticals Company Profile Get Rating , Wall Street , Get Rating , Oramed Pharmaceutical , Investment Mangement , Street Corp , Altium Capital Management , Pharmaceuticals Company Profile , Nasdaq Ormp ,